AVLN - Company ID 0001540171
The table below shows Avalyn Pharma Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 |
|---|---|---|
| Cash & equivalents | $264.20M | $92.31M |
| Short-term investments | $88.23M | $30.82M |
| Receivables | - | - |
| Inventory | - | - |
| Total current assets | $357.99M | $129.99M |
| Property, plant & equipment | $1.21M | $1.26M |
| Goodwill | - | - |
| Total assets | $425.45M | $135.66M |
| Accounts payable | $2.65M | $3.15M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current liabilities |
| $10.81M |
| $11.79M |
| Long-term debt | $14.80M | $14.81M |
| Total liabilities | $27.10M | $27.69M |
| Retained earnings | -$321.17M | -$292.23M |
| Total equity | $398.35M | -$264.25M |